INTRODUCTION
It is known that estradiol (E2) acts on the reproductive system. However, it also has numerous 42 actions on non-reproductive tissues such as bone, the cardiovascular system, the brain and the 43 immune system (Turgeon et al., 2006) . Several studies have reported that the actions of 44 endogenous estrogens could be disrupted by pollutants, particularly xeno-estrogens, a family 45 among endocrine-disrupting chemicals (EDCs) (Colborn et al., 1993; Guillette et al., 1994;  46 Toppari et al., 1996) . The primary environmental problem is that EDCs are widely dispersed 47 in surface water (Campbell et al., 2006) throughout the world and the detected concentrations 48 are mainly linked to waste water treatment plan that is not efficient enough to remove the 49 overall compounds (Hamid and Eskicioglu, 2012) . Their presence in environment constitutes 50 a risk for Human and wildlife. In this context, the European Parliament has recently voted the 51 inclusion in the list of priority substances of the Water Framework Directive, two well-known 52 estrogenic compounds: E2 and 17-ethynylestradiol (EE2), being used as pharmaceuticals 53 (European Parliament News, 2012). These two compounds are present in environment at ng/L 54 and ng/g in river and sediment (Huang et al., 2013; Leusch et al., 2013; Esteban et al., 2014) . 55 Therefore, several in vivo and in vitro methods have been developed to characterize the 56 response of E2 as well as of other EDCs (Andersen et al., 1999; Kerdivel et al., 2013) . In vivo 57 methods utilize different species to study the different physiological functions of estrogens. 58 For example, uterotrophic growth has been studied in rodents (Odum et al., 1997) , 59 vitellogenin expression has been investigated in rainbow trouthepatocytes (Flouriot et al., 60 1995; Sumpter and Jobling, 1995) or modification of life cycle was assessed in zebrafish 61 (Micael et al., 2007) . In vitro approaches were used to investigate the subcellular effects of E2 62 and EDCs that are mediated by estrogen receptor (ER)-dependent mechanisms, particularly 63 transcriptional or membrane-initiated mechanisms (Mendelsohn, 2000; Edwards, 2005) . 64 Transcriptional studies primarily utilize in vitro short-term assays with reporter genes under 65 the control of consensus sequences in their promoters, such as the estrogen response element 66 (ERE) (Petit et al., 1995; Arnold et al., 1996; Andersen et al., 1999; Balaguer et al., 1999) , the 67 AP1-or SP1-binding sites (Fujimoto et al., 2004; Schreihofer, 2005) . In parallel, other in vitro 68 approaches were used to study the global cellular effects of EDCs. For instance, using the E-
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Screen assay, studies report the proliferative effects of EDCs on ER positive breast cancer 70 cells (Soto et al., 1992; Villalobos et al., 1995; Andersen et al., 1999) . If xeno-estrogens have 71 strong proliferative effects, they may also induce differentiating effects on certain tissues such 72 as uterus, blood vessels, heart, bone and brain (Turgeon et al., 2006) . With regard to the brain, 73 many in vivo and in vitro studies have reported a role for E2 in brain protection and 74 functioning (for review see Habauzit et al. 2011) ; however, there is no test currently available 75 to assess the differentiating effects of EDCs in a neuronal context alternative to animal model.
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The PC12 cell line is derived from rat pheochromocytoma, a tumor arising from the 77 adrenal medulla (Greene and Tischler, 1976) and is highly regarded among the in vitro differentiation, using the capacity to extend neurites when treated with nerve growth factor 84 NGF (Gollapudi and Oblinger, 2001) . Moreover the ability of PC12 cells to take into account 85 the dependence on the ER status has also been reported: we previously demonstrated that the 86 stable transfection of PC12 cells with ERα was able to modify differentiation (neurite 
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In this study, our objective was to develop a new tool for the evaluation of the EDC 90 differentiating effect. In this way the EDC effect was evaluate in the context of 91 undifferentiated / differentiated PC12 cells mainly by the evaluation of their ability to act on 92 the classical estrogenic targets: transcription and differentiation. We used the following 93 pharmaceutical products: 17-ethynylestradiol (EE2), which is widely used for birth control 94 (Lobo and Stanczyk, 1994) ; raloxifene (Ral) and 4-hydroxytamoxifen (4-OHT), which are 214 We evaluated the estrogenic activities of classical estrogenic compounds on the 215 transcriptional activity through ERE and SP1 reporter assay in a context of undifferentiated or 216 differentiated cells. In this way these activities were evaluated in PC12 cells treated or not 217 with NGF. As expected, in the PC12 control cells (ER negative), the ERE-TK activity was not 218 modified by either E2 or by the EDCs in the presence or in the absence of NGF treatment 219 (Fig. 1A) . By contrast, in the PC12 cells transiently transfected with ERα, the compounds E2, 220 Gen, EE2 and BPA increased the ERE-TK transcriptional activity, whereas 4-OHT and Ral 221 decreased it whatever the NGF status. Both of these effects occurred in a dose-dependent 222 manner (Fig. 1B) . In the ER negative cells, higher concentrations of BPA and 4-OHT slightly 223 decreased the SP1-Luc activity ( Fig. 2A ). SP1 luciferase activity was regulated in ER The dose-related neuritogenic effects of estradiol or different EDCs were determined 233 on PC12 cells that were stably transfected with either pCR3.1 ERαor the empty vector, 234 pCR3.1. Treatment with NGF (5 ng/mL) for 60 h provoked the neurite outgrowth of PC12 235 control and PC12 ER clones (Fig. 3A) . The expression of ER in PC12 ER cells was confirmed 236 by Western-Blot (Fig. 3B ).
Transcriptional activity of EDCs in undifferentiated and differentiated PC12 cells
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E2 (10 -9 and 10 -8 M) significantly increased the NGF-inducedneurite extension of the 238 PC12 ER clones but not the PC12control clones (Fig. 4A ). Gen (concentrations from 10 -8 to 239 10 -6 M) and 4-OHT (concentrations from 10 -8 to 10 -6 M) also increased the NGF-240 inducedneuritogenesis via an ERα-dependent mechanism ( Fig. 4B-C) . By contrast, EE2, Ral 241 and BPA did not have significant effects on PC12 ER clones treated with NGF ( Fig. 4D-F) . In 242 the absence of NGF, the compounds E2, EE2, Gen, 4-OHT, Ral and BPA did not modify 243 neurite outgrowth of both PC12 ER and PC12 control clones (data not shown). Only the 244 highest concentration of Gen (10 -5 M) inhibited the neurite outgrowth in both the control and 245 PC12 ER clones treated with NGF ( Fig. 4B) and also decreased the ratio adherent cells / total 246 cells (respectively 32 ± 8.5 % and 33.5 ± 12.5 % for PC12 ER and PC12 control clones, when 247 this ratio was near 1 for other conditions (data not shown)). were undetectable in neuro2A cells (Schreihofer, 2005) . These differences underline the 282 SERMs activities of these compounds. We clearly distinguish the activity of E2 from those of 283 SERMs such as 4-OHT to modulate ERE-dependent genes/promoter construct. That was not 284 true when we studied the ability of ER/ SP1 complexe to modulate transcription. Indeed, E2, PC12control ones (Fig. 4A ).We find that among the EDCs, Gen and 4-OHT also display 307 estrogenic effects in PC12 ER clones in a concentration range of 10 -8 M to10 -6 M. By contrast, 308 10 -5 M Gen decreases neuritogenesis, as previously reported for high concentrations of this 309 compound (Bouron et al., 1999) . This inhibition appears to be ER-independent and could be 310 explained by a toxic effect of Gen at this concentration. Indeed, we observed a decrease of 311 more than 60% of adherent cells treated with 10 -5 M Gen that could support this hypothesis. 312 This effect has been already observed in rat primary cortical neurons (Linford et al., 2001) .
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The selective activation of ER by ligands that is dependent upon the tissue environment is extension via an ER-dependent mechanism (Lee et al., 2007) . EE2 is a clinically relevant 336 estrogenic compound that is more potent than E2 and is widely used for birth control (Lobo 337 and Stanczyk, 1994) . With regard to the subcellular or global cellular assays of estrogenicity, 338 10 -10 M to 10 -9 M EE2 can display strong estrogenic activity. It is verified using the ERE- Thus, neuritogenic effects of E2 were suppressed in PC12 cells stably transfected with a DNA 364 binding domain deleted ERα (Merot et al., 2009 ). These different PC12 clones could also be 365 used to characterize the ER domains that are involved in the effects of EDCs. Moreover, these 366 PC12 clones provide the basis for further studies focusing on the effects of EDCs in the 367 specific context of brain development or diseases, which remain poorly documented. 
